HomeInsightsPE

Fredun Pharmaceuticals Ltd P/E Ratio

Fredun Pharmaceuticals Ltd P/E Ratio

download
stocks purchased

₹ 0.5 Cr

Volume transacted

stocks purchased

5.6 K

stocks traded

Last Updated time: 19 Jul 9.00 AM

Image

Fredun Pharmaceuticals Ltd

NSE: FREDUNPHARMA

PE

25.5

Last updated : 19 Jul 9.00 AM

Key Highlights

    The P/E Ratio of Fredun Pharmaceuticals Ltd is 25.5 as of 19 Jul 9.00 AM .a1#The P/E Ratio of Fredun Pharmaceuticals Ltd changed from 37.8 on March 2019 to 32.6 on March 2023 . This represents a CAGR of -2.92% over 5 years. a1#The Latest Trading Price of Fredun Pharmaceuticals Ltd is ₹ 850.05 as of 18 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.5 to 27.2 in 5 years. This represents a CAGR of -0.93%a1# The PE Ratio of Automobile industry is 18.5. The PE Ratio of Finance industry is 24.3. The PE Ratio of IT - Software industry is 29.3. The PE Ratio of Pharmaceuticals industry is 37.0. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 20.4. In 2024a1#The Market Cap of Fredun Pharmaceuticals Ltd changed from ₹ 168.8 crore on March 2019 to ₹ 352.27 crore on March 2023 . This represents a CAGR of 15.85% over 5 years. a1#The Revenue of Fredun Pharmaceuticals Ltd changed from ₹ 48.42 crore to ₹ 118.03 crore over 8 quarters. This represents a CAGR of 56.13% a1#The EBITDA of Fredun Pharmaceuticals Ltd changed from ₹ 3.87 crore to ₹ 11.17 crore over 8 quarters. This represents a CAGR of 69.89% a1#The Net Pr of Fredun Pharmaceuticals Ltd changed from ₹ 0.94 crore to ₹ 5.06 crore over 8 quarters. This represents a CAGR of 132.01% a1#The Dividend Payout of Fredun Pharmaceuticals Ltd changed from 5.82 % on March 2019 to 2.93 % on March 2023 . This represents a CAGR of -12.83% over 5 years. a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

×

Historical P/E Ratio of Fredun Pharmaceuticals Ltd

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Historical P/E Ratio of Fredun Pharmaceuticals Ltd

Period
Mar '1937.8
Mar '2024.4
Mar '2191.8
Mar '2264.1
Mar '2332.6

Company Fundamentals for Fredun Pharmaceuticals Ltd

Market Cap

398 Cr

EPS

33.3

P/E Ratio (TTM) *

25.5

P/B Ratio (TTM) *

3.3

Day’s High

877.95

Day’s Low

838.0

DTE *

0.9

ROE *

12.9

52 Week High

1249.0

52 Week Low

650.0

ROCE *

15.5

* All values are consolidated

Last Updated time: 19 Jul 9.00 AM

* All values are consolidated

Last Updated time: 19 Jul 9.00 AM

Image

Fredun Pharmaceuticals Ltd

NSE: FREDUNPHARMA

PRICE

850.05

-28.60 (-3.25%)

stock direction

Last updated : 18 Jul 15:30

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Fredun Pharmaceuticals Ltd

Strength

1

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

Asset Value vs Market Value of Fredun Pharmaceuticals Ltd

Market Value

398

Asset Value

216

0.8 X

Value addition

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Fredun Pharmaceuticals Ltd25398
Sun Pharmaceuticals Industries Ltd38382,370
Divis Laboratories Ltd75121,646
Cipla Ltd28121,616
Zydus Lifesciences Ltd30119,269
Dr Reddys Laboratories Ltd20111,194

Key Valuation Metric of Fredun Pharmaceuticals Ltd

Earnings

15 Cr

25.5 X

PE Ratio

Market Cap

₹398.18Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Earnings

15 Cr

25.5 X

PE Ratio

Market Cap

₹398.18Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

×

Historical Market Cap of Fredun Pharmaceuticals Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Fredun Pharmaceuticals Ltd

Period
Mar '19169
Mar '2047
Mar '21185
Mar '22406
Mar '23352

* All values are a in crore

×

Historical Revenue of Fredun Pharmaceuticals Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of Fredun Pharmaceuticals Ltd

Period
Jun '2248
Sep '2270
Dec '2278
Mar '2380
Jun '2362
Sep '2382
Dec '2387
Mar '24118

* All values are a in crore

×

Historical EBITDA of Fredun Pharmaceuticals Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of Fredun Pharmaceuticals Ltd

Period
Jun '224
Sep '227
Dec '227
Mar '2312
Jun '238
Sep '2310
Dec '2311
Mar '2411

* All values are a in crore

×

Historical Net Profit of Fredun Pharmaceuticals Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of Fredun Pharmaceuticals Ltd

Period
Jun '221
Sep '223
Dec '223
Mar '234
Jun '232
Sep '234
Dec '234
Mar '245

* All values are a in crore

×

Historical Dividend Payout of Fredun Pharmaceuticals Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Fredun Pharmaceuticals Ltd

Period
Mar '196
Mar '2014
Mar '2114
Mar '225
Mar '233

* All values are a in %

About Fredun Pharmaceuticals Ltd

About Fredun Pharmaceuticals Ltd

    Incorporated in 1987 as a private limited company, Fredun Pharmaceuticals (FPL) was converted into a public limited company in Mar.'94. The Company was promoted by Nariman Medhora and Daulat N Medhora. The promoters initially established D N Pharma, a proprietary firm, for the manufacture and export of pharmaceutical formulations. Since 1993, D N Pharma's operations were phased out in order to switch over the business to FPL. The Company is well diversified in the business ranging from Formulations to Diagnostics to Consultancy. The Company has an unique range of products, from niche formulations , anti-diabetics to the latest antiretroviral and anti - Hypertensive products. It supplies finished formulations to over 42 Countries globally. It is associated with many Governments of different countries which have also realised the need for robust and consistent healthcare systems. The Company was set up with the objective of providing facilities for manufacturing and marketing of various pharmaceutical formulations like tablets, capsules, dry-syrups and ointments. It then set up a formulation unit at Palghar (Thane District), Maharashtra, which commenced commercial production in Aug.'94. FPL had been carrying out manufacturing operations on loan licence for reputed pharmaceutical companies like Cipla. It also manufactured for some merchant exporters, including Merind. In Apr.'96, the company came out with a public issue to register its products in the overseas market for exports; to part-finance the expansion of its business activities and to repay one of the term loans and unsecured loans to reduce the interest burden. Company is very much optimistic of revival of company's turnover by having excellent export order in hand. Company also in process of registering various drugs with different countires such as Nepal, Tanzaniya, Uganda & Sri Lanka. In 2013, Company launched 36 new products and filed 60 new products for registration. It launched a herbal dietary supplement in Africa. During 2015, three new granulation departments were introduced to the existing two departments. It launched 19 new products under the Cosmeceuticals OEM Division in 2023. It introduced 14 new products in the pet pharmaceuticals line, with another 36 in the works. It launched 16 products into the Pet Treat and Nutritional Supplement category.

Fredun Pharmaceuticals Ltd News Hub

News

Board of Fredun Pharmaceuticals recommends final dividend

Fredun Pharmaceuticals announced that the Board of Directors of the Company at its meeting...

Read more

08 May 202409:31

News

Fredun Pharmaceuticals to table results

Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 M...

Read more

25 Apr 202410:30

News

Fredun Pharmaceuticals to conduct board meeting

Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 ...

Read more

06 Feb 202420:34

News

Fredun Pharmaceuticals to conduct EGM

Fredun Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Compa...

Read more

23 Dec 202310:35

News

Fredun Pharmaceuticals to consider fund raising

Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 16 ...

Read more

09 Dec 202310:01

News

Fredun Pharmaceuticals to declare Quarterly Result

Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 8 N...

Read more

03 Nov 202311:25

Product Composition by Percentage (Revenue)

FAQs for PE of Fredun Pharmaceuticals Ltd

What is Fredun Pharmaceuticals Ltd current share price?

The current market price of Fredun Pharmaceuticals Ltd as of July 19, 2024 is ₹850.05.

What is Fredun Pharmaceuticals Ltd's market cap?

Fredun Pharmaceuticals Ltd's market capitalisation stood at ₹398 Cr as of July 19, 2024

What are Fredun Pharmaceuticals Ltd's total net assets?

According to Fredun Pharmaceuticals Ltd's most recent financial filings, the company's net assets total ₹215.9 Cr.

Is Fredun Pharmaceuticals Ltd making a profit or loss?

Fredun Pharmaceuticals Ltd's net Profit as of July 19, 2024 is close to ₹15 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199